Bristol-Myers Squibb and AbbVie have received Breakthrough Therapy Designation from the FDA for elotuzumab, an investigational humanized monoclonal antibody for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.   The designation is based on findings from a Phase II study that evaluated two dose levels of elotuzumab in combination with lenalidomide and low-dose dexamethasone in previously-treated MM patients.   The FDA Breakthrough Designation is intend...